Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05996250
Other study ID # 69HCL22_0203
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 25, 2023
Est. completion date May 28, 2024

Study information

Verified date June 2024
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Spatial navigation is a high-level cognitive function allowing animals and humans to orient and move in space by constructing a mental representation of the environment. This function has been identified as one of the very first to be affected by Alzheimer's disease, including at the early stages, before the appearance of other mnesic disorders that the latter causes, such as those of episodic memory. However, the neuropsychological tests currently used in the diagnosis of cognitive disorders do not allow effective assessment of spatial memory impairment, in particular because it is impractical to offer spatial orientation tasks in a consulting room. In this context, virtual reality offers very interesting perspectives: it makes it possible to create controlled environments to assess spatial memory, without leaving the place of consultation. Before being able to test its possible diagnostic efficacy, it is imperative to test the feasibility as well as the reliability of this type of task on an elderly population with no cognitive impairment. The data currently available on immersion tolerance in virtual reality mainly concern young people aged 18 to 35 and little data is available concerning the elderly or very old. If this task correctly assesses spatial navigation abilities, this study should find the effects of age and sex usually observed. The aim of this study is to assess the tolerance of an immersive virtual reality task evaluating the spatial memory of elderly subjects and the effects of age, gender and level of education on performance.


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date May 28, 2024
Est. primary completion date May 28, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years to 85 Years
Eligibility Inclusion Criteria: - Participant aged 60 to 85 - Participant affiliated or entitled to a social security scheme - Recruited participants must have been informed and consented in writing Exclusion Criteria: - Participant with a diagnosis of cognitive impairment - Severe, progressive or unstable pathology whose nature may interfere with the evaluation variables (epilepsy, psychiatric or psychotic disorders in the acute phase, visual hallucinations, acute infection, lack of sleep) - Participant equipped with a pacemaker - Burns or sores on the upper part of the face or on the scalp - Consumption of toxic substances that can influence cognitive performance - Deafness or blindness that may compromise participant assessment or completion of tasks and scales - Participant under guardianship or curatorship or legal safeguard - Participant refusing to use an immersive virtual reality tool - Criterion for stopping the procedure under study: stopping the virtual reality task due to the participant's simulator sickness. - Montreal Cognitive Assessment (MOCA) score less than 26 - MacNair Subjective Complaint Scale score greater than 16 - AGGIR score (Autonomy, Gerontology Group Iso Resources) less than 5

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Immersive virtual reality task
participants will have to wear a virtual reality headset connected to a remote control and will have to perform submersive virtual reality tasks

Locations

Country Name City State
France Charpennes Geriatric Hospital, Lyon University Hospital Villeurbanne

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sickness Simulator Questionnaire (SSQ) score This is a questionnaire composed of 16 items covering the potential symptoms of intolerance to a virtual reality tool.
Each item is rated 0 (no symptom), 1 (mild symptom), 2 (moderate symptom) or 3 (severe symptom). The total score is obtained by multiplying the sum of the items by 3.74, and therefore varies from 0 to 180.
The sickness simulator scale is assessed immediately after the immersive virtual reality task.
Secondary Time to complete the task in immersive virtual reality according to the age of the participants Time to complete the task in immersive virtual reality (in seconds) according to the age of participants (in years) through study completion, 1 year
Secondary Time to complete the task in immersive virtual reality (in seconds) according to the gender of participants (male or female) Time to complete the task in immersive virtual reality according to the gender of participants through study completion, 1 year
Secondary Time to complete the task in immersive virtual reality according to the number of years of study Time to complete the task in immersive virtual reality (in seconds) according to the number of years of study (from entry into primary school) through study completion, 1 year
Secondary Raw score on the Wechsler Memory Scale-III (MEM III) Spatial Memory subtest The test is designed for adults and the elderly to assess the performance of auditory memory, visual memory, memory immediate, delayed and visual working memory.The subtest used is the Spatial Memory subtest, it ranges from 0 to 28 (the higher the score, the better the performance). through study completion, 1 year
See also
  Status Clinical Trial Phase
Completed NCT05445440 - A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine Phase 1
Completed NCT03712540 - An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants Phase 1
Completed NCT03649165 - A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants Phase 1
Completed NCT05956002 - A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants Phase 1
Completed NCT05539976 - A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants
Withdrawn NCT04558216 - Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants Phase 1
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT06097390 - A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III Phase 1
Completed NCT05546151 - A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent Phase 1
Completed NCT05056246 - Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants Phase 1
Completed NCT04390776 - Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules. Phase 1
Completed NCT05074459 - A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines Phase 1
Enrolling by invitation NCT06089109 - Creating VIP Corps to Reduce Maternal Deaths N/A
Completed NCT03278080 - Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1 N/A
Completed NCT05064800 - PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants Phase 1
Completed NCT04471298 - A Study of Qishenyiqi Dripping Pills in Healthy Participants Phase 1
Completed NCT04914936 - A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196 Phase 1
Completed NCT01681186 - A Study of LY2940680 in Healthy Participants Phase 1
Completed NCT02882386 - Amino Acid Kinetics in Blood After Consuming Different Milk Protein Supplements N/A
Completed NCT02563262 - Human Neutral Body Posture in Weightlessness N/A